Pharmaceutical Raw Powder Pramipexole for Mirapex Sport Nutrition (104632-26-0)

Pharmaceutical Raw Powder Pramipexole for Mirapex Sport Nutrition (104632-26-0)

Basic info:

Pramipexole

Synonyms: Pramipexole;Mirapex;(S)-2-Amino-6-propylamino-4, 5, 6, 7-tetrahydrobenzthiazole

CAS: 104632-26-0

EINECS: 245-669-1

Assay: 99.8%(HPLC)

MF: C10H17N3S

MW: 211.33

Apprarance: White Powder

Product info:

Pramipexole dihydrochloride is a non-ergoline dopamine agonist indicated for treating early-stage Parkinson's disease (PD) andrestless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache and to counteract the problems with sexual dysfunction experienced by some users of the selective serotonin reuptake inhibitor (SSRI) antidepressants. Pramipexole has shown robust effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder. It is also being investigated for the treatment of clinical depression and fibromyalgia.

Applications:

Treating the signs and symptoms of Parkinson disease. It is also used to treat restless legs syndrome (RLS).: Pramipexole is a non-ergoline dopamine agonist indicated for treating early-stage Parkinson's disease (PD) and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache and to counteract the problems with sexual dysfunction experienced by some users of the selective serotonin reuptake inhibitor (SSRI) antidepressants. Pramipexole has shown robust effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder. It is also being investigated for the treatment of clinical depression and fibromyalgia. It may also be used for other conditions as determined by your doctor.Pramipexole is a dopamine agonist. Exactly how pramipexole works is not known. It may increase the action of certain chemical receptors in the brain.

To alleviate the symptoms of Parkinson's disease: Parkinson's disease is due to the movement of brain dopaminergic neuron loss caused by dopamine deficiency, lead to patients with tremor, rigidity and bradykinesia and a series of symptoms. Hydrochloric acid highly selective effects on dopamine D2 and D3 receptor agonist, dopamine release, improve motor symptoms. Research on Shannon display, early Parkinson's disease patients pramipexole monotherapy after, can effectively control the motor symptoms in patients with early stage, to help maintain the ability of daily life. Pramipexole in combination with levodopa can effectively improve the ADL score and motor symptoms in patients with advanced Parkinson's disease score in patients with advanced Parkinson's disease, make life more vibrant.